Inhibitory effect of adefovir on viral DNA synthesis and covalently closed circular DNA formation in duck hepatitis B virus-infected hepatocytes in vivo and in vitro

Antimicrobial Agents and Chemotherapy

Volumn 46, Issue 2, 2002, Pages 425-433

  Delmas, Julien ^a   Schorr, Olivier ^a   Jamard, Catherine ^a   Gibbs, Craig ^a   Trépo, Christian ^a   Hantz, Olivier ^a   Zoulim, Fabien ^a  

^a INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ADEFOVIR DIPIVOXIL; CIRCULAR DNA; LAMIVUDINE; PHOSPHONIC ACID DERIVATIVE; VIRUS DNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC THERAPY; ARTICLE; CONTROLLED STUDY; COVALENT BOND; DNA SYNTHESIS INHIBITION; DRUG EFFECT; DRUG POTENCY; DUCK; FETUS; GENE AMPLIFICATION; HEPATITIS B; HEPATITIS B VIRUS; IN VITRO STUDY; IN VIVO STUDY; INFECTION PREVENTION; INOCULATION; LIVER CELL; NONHUMAN; PRIORITY JOURNAL; RECURRENT INFECTION; VIREMIA; VIRION; VIRUS GENOME; VIRUS INHIBITION;

ADENINE; ANIMALS; ANTIVIRAL AGENTS; DISEASE MODELS, ANIMAL; DNA, CIRCULAR; DNA, VIRAL; DUCKS; HEPATITIS B; HEPATITIS B VIRUS, DUCK; HEPATOCYTES; PHOSPHONIC ACIDS;

EID: 0036148731     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.46.2.425-433.2002     Document Type: Article

References (50)

1. Inhibitory effect of 2′-fluoro-5-methyl-β-L-arabinofuranosyl-uracil on duck hepatitis B virus replication
2. Initial amplification of duck hepatitis B virus covalently closed circular DNA after in vitro infection of embryonic duck hepatocytes is increased by cell cycle progression
3. Phosphorylation of DHBV pre-S: Identification of the major site of phosphorylation and effects of mutations on the virus life cycle
4. Enhancement of natural killer activity and interferon induction by different acyclic nucleoside phosphonates
5. The half-life of duck hepatitis B virus supercoiled DNA in congenitally infected primary hepatocyte cultures
6. In vitro antihepadnaviral activities of combinations of penciclovir, lamivudine, and adefovir
7. Synergistic inhibition of hepadnaviral replication by lamivudine in combination with penciclovir in vitro
8. Oral bioavailability of the antiretroviral agent 9-(2-phosphonylmethoxyethyl)adenine (PMEA) from three formulations of the prodrug bis(pivaloyloxymethyl)-PMEA in fasted male cynomolgus monkeys
9. Increased hepatocyte turnover and inhibition of woodchuck hepatitis B virus replication by adefovir in vitro do not lead to reduction of the closed circular DNA
10. Lamivudine as initial treatment for chronic hepatitis B in the United States
11. Molecular anatomy and pathophysiologic implications of drug resistance in hepatitis B virus infection
12. Application of the neutral red assay (NR assay) to monolayer cultures of primary hepatocytes: Rapid colorimetric viability determination for the unscheduled DNA synthesis test (UDS)
13. Evidence that hepatocyte turnover is required for rapid clearance of duck hepatitis B virus during antiviral therapy of chronically infected ducks
14. Characterization of novel human hepatoma cell lines with stable hepatitis B virus secretion for evaluating new compounds against lamivudine- and penciclovir-resistant virus
15. A placebo-controlled phase I/II study of adefovir dipivoxil in patients with chronic hepatitis B virus infection
16. Viral clearance without destruction of infected cells during acute HBV infection
17. Apoptosis and regeneration of hepatocytes during recovery from transient hepadnavirus infections
18. Inhibitory effect of 9-(2-phosphonyl-methoxyethyl)adenine (PMEA) on human and duck hepatitis-B virus infection
19. Inhibitory effects of acyclic nucleoside phosphonates on human hepatitis B virus and duck hepatitis B virus infections in tissue culture
20. Drug therapy: The treatment of chronic viral hepatitis
21. Rapid resolution of duck hepatitis B virus infections occurs after massive hepatocellular involvement
22. In vitro model for the nuclear transport of the hepadnavirus genome
23. Analysis of the earliest steps of hepadnavirus replication: Genome repair after infectious entry into hepatocytes does not depend on viral polymerase activity
24. Antiviral agents in hepatitis B virus transfected cell lines: Inhibitory and cytotoxic effect related to time of treatment
25. A one-year trial of lamivudine for chronic hepatitis B
26. Virus-neutralizing monoclonal antibody to a conserved epitope on the duck hepatitis B virus pre-S protein
27. Combination therapy with lamivudine and famciclovir for chronic hepatitis B-infected Chinese patients: A viral dynamics study
28. Hepatitis B virus infection
29. Characterization of the antiviral effect of 2′,3′-dideoxy-2′,3′-didehydro-beta-L-5-fluorocytidine in the duck hepatitis B virus infection model
30. Antiviral chemotherapy for chronic hepatitis B infection: Lessons learned from treating HIV-infected patients
31. Long-term ganciclovir chemotherapy for congenital duck hepatitis B virus infection in vivo: Effect on intrahepatic-viral DNA, RNA, and protein expression
32. Lamivudine therapy of WHV-infected woodchucks
33. Characterization of the antiviral effects of 2′ carbodeoxy-guanosine in ducks chronically infected with duck hepatitis B virus
34. Lack of effect of antiviral therapy in nondividing hepatocyte cultures on the closed circular DNA of woodchuck hepatitis virus
35. Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B
36. The covalently closed duplex form of the hepadnavirus genome exists in situ as a heterogeneous population of viral minichromosomes
37. Inhibition of duck hepatitis B virus replication by 9-(2-phosphonylmethoxyethyl)adenine, an acyclic phosphonate nucleoside analogue
38. Viral dynamics in hepatitis B virus infection
39. The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance
40. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants
41. Protective and therapeutic effect of DNA-based immunization against hepadnavirus large envelope protein
42. Duck hepatitis B virus polymerase gene mutants associated with resistance to lamivudine have a decreased replication capacity in vitro and in vivo
43. Hepadnavirus envelope proteins regulate covalently closed circular DNA amplification
44. Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy
45. n-butyrate, a cell cycle blocker, inhibits early amplification of duck hepatitis B virus covalently closed circular DNA after in vitro infection of duck hepatocytes
46. Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells
47. In hepatocytes infected with duck hepatitis B virus, the template for viral RNA synthesis is amplified by an intracellular pathway
48. Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro
49. Kinetics of hepadnavirus loss from the liver during inhibition of viral DNA synthesis
50. Drug therapy for chronic hepatitis B: Antiviral efficacy and influence of hepatitis B virus polymerase mutations on the outcome of therapy